Autolus Therapeutics Raises $100M Via Equity

Autolus Therapeutics PLC (NASDAQ: AUTL) prices an underwritten public offering in the U.S. of 14.3 million American Depositary Shares (ADS) representing 14.3 million ordinary shares at $7 per ADS, for total gross proceeds of approximately $100 million. Underwriters have an option to purchase up to an additional 2.1 million ADSs.
The offering is expected to close on February 12.
J.P. Morgan and Wells Fargo Securities are acting as joint book-runners for the offering.
Autolus did not mention the use for the proceeds raised. Still, last month, it prioritized the development of AUTO1 and thus planned to cut headcount by approximately 20% resulting in annualized savings of $15 million. AUTO1 is under development for adult acute lymphoblastic leukemia, with full data from the AUTO1-AL1 study expected in 2022.
Autolus plans to seek a partner for the AUTO3 program, its CAR T product candidate for relapsed/refractory diffuse large B cell lymphoma, ahead of progressing into the next phase of development.
Price Action: AUTL slid 2% at $7.35 during the premarket trading on the last check Wednesday.